Literature DB >> 31594400

Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.

Shraddha Narechania1, Heather Torbic2, Adriano R Tonelli1.   

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors in the management of this disease. Poor adherence to treatment is a common problem in PAH as it is in many chronic diseases. Management of medication interruptions is a challenge in patients with PAH that can lead to negative consequences. However, for most PAH-specific drugs, there are no clear guidelines on how to manage temporary or abrupt medication discontinuations. In this review, we summarized the available literature and provide suggestions on how to manage interruptions of PAH-specific therapies.

Entities:  

Keywords:  discontinuation; pulmonary arterial hypertension; pulmonary hypertension; treatment; treatment interruption

Year:  2019        PMID: 31594400     DOI: 10.1177/1074248419877409

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  3 in total

1.  Pause at Your Own Peril: A Case Series on Rebound Pulmonary Hypertension.

Authors:  Sindhubarathi Murali; Subrat Khanal; Sanchari Banerjee; Omari Christie; Kartik Ramakrishna
Journal:  Cureus       Date:  2022-05-31

2.  Perillyle alcohol and Quercetin ameliorate monocrotaline-induced pulmonary artery hypertension in rats through PARP1-mediated miR-204 down-regulation and its downstream pathway.

Authors:  Soodeh Rajabi; Hamid Najafipour; Saeideh Jafarinejad Farsangi; Siyavash Joukar; Ahmad Beik; Maryam Iranpour; Zeinab Kordestani
Journal:  BMC Complement Med Ther       Date:  2020-07-13

3.  Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Barbro Kjellström; Anna Sandqvist; Clara Hjalmarsson; Magnus Nisell; Per Näsman; Bodil Ivarsson
Journal:  ERJ Open Res       Date:  2020-12-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.